New BTK blocker aims to outsmart drug resistance in elderly CLL patients

NCT ID NCT07685717

Recruiting now Disease control Sponsor: Jennifer Woyach Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 2 trial tests a drug called pirtobrutinib in people aged 75 and older with untreated chronic lymphocytic leukemia (CLL). Pirtobrutinib is a next-generation BTK inhibitor designed to block cancer growth signals, potentially working even when other similar drugs stop being effective. Researchers want to see if it can control the disease with fewer side effects and less risk of resistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirtobrutinib
What this could lead to: If successful, pirtobrutinib could offer a more effective and tolerable treatment option for elderly patients with chronic lymphocytic leukemia, potentially overcoming resistance to other BTK inhibitors.
What could go wrong: This is a phase 2 trial with only 50 participants, so results are preliminary. The drug may not prove more effective than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.